Anticipated $-0.18 EPS for Pulmatrix, Inc. (PULM) as of May, 4

May 3, 2018 - By Anthony Rauscher

Pulmatrix, Inc. (NASDAQ:PULM) Corporate Logo

Investors expect Pulmatrix, Inc. (NASDAQ:PULM)’s quarterly earnings on May, 4., as reported by Faxor. EPS of $-0.18 is 14.29 % up from 2017’s $-0.21 EPS. Ticker’s shares touched $0.466 during the last trading session after 1.41% change.Currently Pulmatrix, Inc. is downtrending after 74.35% change in last May 3, 2017. PULM has 422,042 shares volume. PULM underperformed the S&P500 by 85.90%.

Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology.The company has $18.76 million market cap. The company's proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis (IPF).Currently it has negative earnings. It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.